{"entity":{"id":"aop-health","kind":"company","name":"AOP Health","aka":["AOP Orphan Pharmaceuticals AG","AOP Orphan","AOP Orphan Pharmaceuticals"],"tldr":"AOP Health is a Vienna rare-disease company that brought ropeginterferon alfa-2b (Besremi) to the European market for polycythaemia vera and runs trials in myeloproliferative neoplasms and other rare conditions.","summary":"AOP Health (formerly AOP Orphan Pharmaceuticals) is a privately held Austrian company focused on rare diseases and intensive care medicine. In cancer it licensed ropeginterferon alfa-2b from PharmaEssentia for Europe and other territories, obtained European approval for polycythaemia vera in 2019 under the name Besremi, and sponsors phase 3 trials of the drug in myeloproliferative neoplasms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.aop-health.com"},{"label":"ClinicalTrials.gov: trials led by AOP Orphan Pharmaceuticals","url":"https://clinicaltrials.gov/search?lead=AOP%20Orphan%20Pharmaceuticals"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Vienna","country":"AT","companyType":"pharma","website":"https://www.aop-health.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/aop-health/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}]}}